Cloning and DNA sequence of a 29 kilodalton polypeptide gene of Mycoplasma gallisepticum as a possible protective antigen

Saito, Shuji; Fujisawa, Ayumi; Ohkawa, Setsuko; Nishimura, Nobukazu; Abe, Takaharu; Kodama, Kazumi; Kamogawa, K.; Aoyama, S; Iritani, Yoshikazu; Hayashi, Yoshiyuki

doi:10.1016/0264-410x(93)90134-j

Cited by 9 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There has been little success with subunit vaccines or recombinant proteins (35), and this is especially true for CBPP, for which the only Office International des Epizootes-recommended vaccines are freeze-dried live formulations (strain T 1 44 or its streptomycin-resistant derivative T 1 SR). Research designed to produce "next-generation" vaccines (e.g., immunostimulating complex [ISCOM], capsular polysaccharide conjugate, or a whole-cell inactivated vaccine) has proceeded, although with little apparent success (2,11,28,39).…”

Section: Discussionmentioning

confidence: 99%

Phage Library Screening for the Rapid Identification and In Vivo Testing of Candidate Genes for a DNA Vaccine against Mycoplasma mycoides subsp. mycoides Small Colony Biotype

et al. 2006

View full text Add to dashboard Cite

A new strategy for rapidly selecting and testing genetic vaccines has been developed, in which a whole genome library is cloned into a bacteriophage ZAP Express vector which contains both prokaryotic (P lac ) and eukaryotic (P CMV ) promoters upstream of the insertion site. The phage library is plated on Escherichia coli cells, immunoblotted, and probed with hyperimmune and/or convalescent-phase antiserum to rapidly identify vaccine candidates. These are then plaque purified and grown as liquid lysates, and whole bacteriophage particles are then used directly to immunize the host, following which P CMV -driven expression of the candidate vaccine gene occurs. In the example given here, a semirandom genome library of the bovine pathogen Mycoplasma mycoides subsp. mycoides small colony (SC) biotype was cloned into ZAP Express, and two strongly immunodominant clones, -A8 and -B1, were identified and subsequently tested for vaccine potential against M. mycoides subsp. mycoides SC biotype-induced mycoplasmemia. Sequencing and immunoblotting indicated that clone -A8 expressed an isopropyl-␤-D-thiogalactopyranoside (IPTG)-inducible M. mycoides subsp. mycoides SC biotype protein with a 28-kDa apparent molecular mass, identified as a previously uncharacterized putative lipoprotein (MSC_0397). Clone -B1 contained several full-length genes from the M. mycoides subsp. mycoides SC biotype pyruvate dehydrogenase region, and two IPTG-independent polypeptides, of 29 kDa and 57 kDa, were identified on immunoblots. Following vaccination, significant anti-M. mycoides subsp. mycoides SC biotype responses were observed in mice vaccinated with clones -A8 and -B1. A significant stimulation index was observed following incubation of splenocytes from mice vaccinated with clone -A8 with whole live M. mycoides subsp. mycoides SC biotype cells, indicating cellular proliferation. After challenge, mice vaccinated with clone -A8 also exhibited a reduced level of mycoplasmemia compared to controls, suggesting that the MSC_0397 lipoprotein has a protective effect in the mouse model when delivered as a bacteriophage DNA vaccine. Bacteriophage-mediated immunoscreening using an appropriate vector system offers a rapid and simple technique for the identification and immediate testing of putative candidate vaccines from a variety of pathogens.Whole bacteriophage (phage) particles have recently been described as highly efficient DNA vaccine delivery vehicles (6,7,17,20), inducing significant antibody responses in both laboratory mice (7) and larger animals such as rabbits (20) and sheep (33). Bacteriophages are viruses of bacteria and are metabolically inert, requiring the host bacterium for growth and propagation. Using standard "naked" DNA vaccination, purified genetic material in the form of a plasmid encoding protective antigens is given to the host and used to stimulate an immune response and give protection against pathogens (37,42). With bacteriophage genetic immunization, expression cassettes containing a vaccine gene under the control of a su...

show abstract

Section: Discussionmentioning

confidence: 99%

Phage Library Screening for the Rapid Identification and In Vivo Testing of Candidate Genes for a DNA Vaccine against Mycoplasma mycoides subsp. mycoides Small Colony Biotype

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The growth inhibition assay without complement was performed essentially as described previously (27). In brief, M. gallisepticum R strain was grown in Chanock's modified medium at 37°C for 3 days, filtered through a 0.45-m (pore-size) membrane filter, and diluted to 1.2 ϫ 10 3 CFU/ ml.…”

Section: Methodsmentioning

confidence: 99%

“…We have focused on the identification and structural analysis of M. gallisepticum surface antigens which are prominent targets of the chicken immune responses and may influence key host interactions (27). The attachment of M. gallisepticum to mucosal epithelium of the respiratory tract of birds is thought to be prerequisite for infection and disease (19).…”

mentioning

confidence: 99%

Identification and Expression of a Mycoplasma gallisepticum Surface Antigen Recognized by a Monoclonal Antibody Capable of Inhibiting Both Growth and Metabolism

Yoshida¹,

Fujisawa²,

Tsuzaki³

et al. 2000

Infect Immun

Self Cite

View full text Add to dashboard Cite

show abstract

“…As S1 is a major immunoprotective protein, many studies have utilized it to immunize chickens against IBV, with promising results (Cavanagh et al, 1984;Johnson et al, 2003;Kapczynski et al, 2003;Gelb et al, 2005;Lokugamage et al, 2008;Tao & Luo, 2009;Zhang et al, 2012). With regard to MG, the TM-1 protein is important for bacterial adherence to the host cell (Saito et al, 1993;Hao et al, 2004;Feng et al, 2013). Like S1, the TM-1 protein has been shown to be capable of inducing protective immunity in chickens (Saito et al, 1993;Hao et al, 2004;Feng et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

“…With regard to MG, the TM-1 protein is important for bacterial adherence to the host cell (Saito et al, 1993;Hao et al, 2004;Feng et al, 2013). Like S1, the TM-1 protein has been shown to be capable of inducing protective immunity in chickens (Saito et al, 1993;Hao et al, 2004;Feng et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Development and evaluation of novel recombinant adenovirus-based vaccine candidates for infectious bronchitis virus and Mycoplasma gallisepticum in chickens

Zhang

Long

et al. 2018

Avian Pathology

View full text Add to dashboard Cite

Avian infectious bronchitis caused by the infectious bronchitis virus (IBV), and mycoplasmosis caused by Mycoplasma gallisepticum (MG) are two major respiratory diseases in chickens that have resulted in severe economic losses in the poultry industry. We constructed a recombinant adenovirus that simultaneously expresses the S1 spike glycoprotein of IBV and the TM-1 protein of MG (pBH-S1-TM-1-EGFP). For comparison, we constructed two recombinant adenoviruses (pBH-S1-EGFP and pBH-TM-1-EGFP) that express either the S1 spike glycoprotein or the TM-1 protein alone. The protective efficacy of these three vaccine constructs against challenge with IBV and/or MG was evaluated in specific pathogen free chickens. Groups of seven-day-old specific pathogen free chicks were immunized twice, two weeks apart, via the oculonasal route with the pBH-S1-TM-1-EGFP, pBH-S1-EGFP, or pBH-TM-1-EGFP vaccine candidates or the commercial attenuated infectious bronchitis vaccine strain H52 and MG vaccine strain F-36 (positive controls), and challenged with virulent IBV or MG two weeks later. Interestingly, by days 7 and 14 after the booster immunization, pBH-S1-TM-1-EGFP-induced antibody titre was significantly higher (P < 0.01) compared to attenuated commercial IBV vaccine; however, there was no significant difference between the pBH-S1-TM-1-EGFP and attenuated commercial MG vaccine groups (P > 0.05). The clinical signs, the gross, and histopathological lesions scores of the adenovirus vaccine constructs were not significantly different from that of the attenuated commercial IBV or MG vaccines (positive controls) (P > 0.05). These results demonstrate the potential of the bivalent pBH-S1-TM-1-EGFP adenovirus construct as a combination vaccine against IB and mycoplasmosis.

show abstract

Cloning and DNA sequence of a 29 kilodalton polypeptide gene of Mycoplasma gallisepticum as a possible protective antigen

Cited by 9 publications

References 30 publications

Phage Library Screening for the Rapid Identification and In Vivo Testing of Candidate Genes for a DNA Vaccine against Mycoplasma mycoides subsp. mycoides Small Colony Biotype

Phage Library Screening for the Rapid Identification and In Vivo Testing of Candidate Genes for a DNA Vaccine against Mycoplasma mycoides subsp. mycoides Small Colony Biotype

Identification and Expression of a Mycoplasma gallisepticum Surface Antigen Recognized by a Monoclonal Antibody Capable of Inhibiting Both Growth and Metabolism

Development and evaluation of novel recombinant adenovirus-based vaccine candidates for infectious bronchitis virus and Mycoplasma gallisepticum in chickens

Contact Info

Product

Resources

About